IN8bio, Inc. (INAB)
Nasdaq · Healthcare · Biotechnology
$1.42+1.43%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $14.0M
- 52-week range
- $0.88 – $2.73
- 52-week change
- −43.09%
- EPS (trailing)
- −$1.62
Fiscal year to Dec 2025
- Net income
- −$19.4M
- Diluted EPS
- −$4.44
From the company’s annual report on SEC EDGAR.
About IN8bio, Inc.
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer; and INB-600, a gamma-Delta T cell engager. In addition, it is developing INB-619, a gamma-delta TCE targeting CD19 for potential applications in both oncology and autoimmune diseases.
Headquarters: New York, United States · 18 employees · in8bio.com